Sanofi halts trials of IL-6 drug for Covid-19, India to continue with trial of another drug of similar class
The decision casts a shadow on other similar classes of drugs such as Tocilizumab by Swiss drug maker Roche pharma, that are under trial for treating Covid-19 in countries including India. However, the investigator leading the Tocilizumab trial in India told ET that the efficacy of these drugs on moderate Covid-19 patients still needs to be studied. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 6, 2020 Category: Pharmaceuticals Source Type: news
Tocilizumab Shows Promise for Treatment of COVID-19
WEDNESDAY, June 24, 2020 -- Use of tocilizumab to target cytokine release syndrome (CRS) seems beneficial for patients with COVID-19, according to a study published online June 15 in CHEST.
Christina C. Price, M.D., from the Yale University School... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 24, 2020 Category: Pharmaceuticals Source Type: news
Tocilizumab Might Help Curb Severe COVID-19
TUESDAY, June 23, 2020 -- Could a drug used in cancer treatment spare hospital patients from the ravages of severe COVID-19?
Yale doctors think it can after giving the medication, known as tocilizumab, to severely ill patients back in March.
How... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 23, 2020 Category: General Medicine Source Type: news
Repurposed drug shows promise for treating COVID-19 inflammation
Yale clinicians report promising results after treating COVID-19 with the drug tocilizumab, which is known to reduce inflammation in chemotherapy patients. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 18, 2020 Category: Universities & Medical Training Source Type: news
U.K. Researchers Say They Have Found First Drug that Improves COVID-19 Survival
Researchers in England say they have the first evidence that a drug can improve COVID-19 survival: A steroid called dexamethasone reduced deaths by up to one third in severely ill hospitalized patients.
Results were announced Tuesday and researchers said they would publish them soon. The study is a large, strict test that randomly assigned 2,104 patients to get the drug and compared them with 4,321 patients getting only usual care.
The drug was given either orally or through an IV. It reduced deaths by 35% in patients who needed treatment with breathing machines and by 20% in those only needing supplemental oxygen. It did ...
Source: TIME: Science - June 16, 2020 Category: Science Authors: MARILYNN MARCHIONE /AP Tags: Uncategorized Source Type: news
Remdesivir, tocilizumab being considered for 'restricted use' on severely ill COVID-19 patients
The much-touted anti-malarial drug hydroxychloroquine will continue to be used while azythromycin may be dropped from the treatment protocol, sources in the know of the developments told . (Source: The Economic Times)
Source: The Economic Times - June 10, 2020 Category: Consumer Health News Source Type: news
Arthritis drug reduced the risks of dying of coronavirus by nearly half in a small study
A new study from the University of Michigan found that tocilizumab, a rheumatoid arthritis drug, reduced the liklihood of death for coronavirus patients on ventilators by 45%. (Source: the Mail online | Health)
Source: the Mail online | Health - June 4, 2020 Category: Consumer Health News Source Type: news
Roche ’s Elecsys IL-6 test receives FDA Emergency Use Authorization to help in identifying patients at high risk of severe inflammatory response
Basel, 4 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the Elecsys ® IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and can be used to help identify patients with confirmed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. The test can support physicians, in combination with other examinations and vital signs, to decide early on if a patient with confirmed COVID-19 illness requires mechanical ventilation. “The FDA E...
Source: Roche Investor Update - June 4, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s Elecsys IL-6 test receives FDA Emergency Use Authorization to help in identifying patients at high risk of severe inflammatory response
Basel, 04 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the Elecsys® IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and can be used to help identify patients with confirm ed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. The test can support physicians, in combination with other examinations and vital signs, to decide early on if a patient with confirmed COVID-19 illness requires mechanical ventilation. “The F...
Source: Roche Media News - June 4, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s Elecsys IL-6 test receives FDA Emergency Use Authorisation to help in identifying patients at high risk of severe inflammatory response
Basel, 4 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorisation (EUA) for the Elecsys ® IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and can be used to help identify patients with confirmed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. The test can support physicians, in combination with other examinations and vital signs, to decide early on if a patient with confirmed COVID-19 illness requires mechanical ventilation. “The FDA E...
Source: Roche Investor Update - June 4, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s Elecsys IL-6 test receives FDA Emergency Use Authorisation to help in identifying patients at high risk of severe inflammatory response
Basel, 04 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorisation (EUA) for the Elecsys® IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and can be used to help identify patients with confirm ed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. The test can support physicians, in combination with other examinations and vital signs, to decide early on if a patient with confirmed COVID-19 illness requires mechanical ventilation. “The F...
Source: Roche Media News - June 4, 2020 Category: Pharmaceuticals Source Type: news
Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc. (Source: World Pharma News)
Source: World Pharma News - May 28, 2020 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
Basel, 28 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc. (Source: Roche Media News)
Source: Roche Media News - May 28, 2020 Category: Pharmaceuticals Source Type: news
Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
·Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra ®/RoActemra® (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer. (Source: Roche Investor Update)
Source: Roche Investor Update - May 28, 2020 Category: Pharmaceuticals Source Type: news
Dilemma for doctors as Roche ’s Covid drug is ‘life-saver’ but too costly
In India, the drug sold under the brand name Actemra, is approved for the use in autoimmune disease such as rheumatoid arthritis and for six months treatment it costs Rs 2.5 lakh. For Covid-19 patients who are administered this drug, the cost is Rs 60,000 per dosage. (Source: The Economic Times)
Source: The Economic Times - May 19, 2020 Category: Consumer Health News Source Type: news
